Clinical trials: Central Blood Pressure
Hypertension
A Study Evaluating the Effects of Nebivolol on Blood Pressure in Hypertensive Patients
The purpose of this study is to evaluate the effects of various doses of nebivolol in patients with mild to moderate hypertension.
- Trial name
- NCT00200460
- Testing
- Nebivolol
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Mylan Bertek Pharmaceuticals
Blood Pressure, Hypertension
Pivotal Clinical Trial to Evaluate the Blood Pressure Accuracy of 'CART-I Plus'
The goal of this clinical trial is to evaluate how accurately the CART-I plus developed by Sky Labs can measure blood pressure. The primary endpoint of this clinical trial is accuracy (mmHg) of 'CART-I plus' which is obtained by…
- Conditions
- Blood Pressure, Hypertension, Hypotension
- Trial name
- NCT05725148
- Testing
- CART-I plus
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sky Labs
Essential Hypertension, Metabolic Syndrome
A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
This is a multi-center, randomized, open-label, active comparator-controlled, phase 4 clinical trial to evaluate the blood pressure control of Telmisartan or Losartan in essential hypertensive patients with metabolic syndrome
- Trial name
- PRISTINE (NCT05843162)
- Testing
- Telmisartan, Losartan
- Volunteers
- 116 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Kidney Diseases
Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage…
- Trial name
- Clarion-CKD (NCT04968184)
- Testing
- KBP-5074
- Where
- 215 sites in United States, Australia and 20 more
- Volunteers
- 666 people
- Sponsor
- Novo Nordisk A/S
Hypertension
Retrospective Survey for Patients With Hypertension and Diabetes Mellitus
This study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of hypertension patients having Type 2…
- Trial name
- CRYSTAL (NCT00681278)
- Where
- 13 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
CNS Disease
Blood-Brain Barrier Penetration of Therapeutic Agents in Human
This is a phase 1, open-label, non-randomized, exploratory, repeated dose PK study performed at a single centre. Up to 6 evaluable subjects are planned. The subjects will receive p.o. doses of ODM-104 for 5-7 days.
- Trial name
- BRIAN (NCT04571996)
- Testing
- ODM-104, Paracetamol
- Where
- Finland
- Volunteers
- 4 people
- Sponsor
- Orion Corporation, Orion Pharma
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Hypertension
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
- Trial name
- NCT00219037
- Testing
- aliskiren
- Where
- Germany
- Volunteers
- 1,955 people
- Sponsor
- Novartis
Hypotension
Clinical Validation of Vital-PICASO for Predicting Hypotension Within 24 Hours in General Ward Inpatients
This retrospective study evaluated the clinical performance of Vital-PICASO, an artificial intelligence-based biological signal analysis software designed to predict the risk of hypotension within 24 hours using vital-sign data…
- Trial name
- NCT07742930
- Where
- South Korea
- Volunteers
- 648 people
- Sponsor
- Huinno AIM
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Hypertension
Hypertensive Treatment Pattern Survey for Type II Diabetes Mellitus Patients With Complication and Hypertension
This study will address the treatment rate and control rate of hypertension, treatment pattern and factors to affect blood pressure control by examining (retrospective) medical records of Type II DM patients with DM related…
- Trial name
- CRYSTAL-CO (NCT00771069)
- Where
- 13 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Hypertension
Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension
This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.
- Trial name
- NCT00160225
- Testing
- Daglutril
- Where
- Italy
- Sponsor
- Solvay Pharmaceuticals
Systolic Hypertension
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
- Trial name
- NCT01281306
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 90 sites in United States, Argentina and 7 more
- Volunteers
- 910 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Dyslipidemias
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive…
- Trial name
- NCT05660135
- Testing
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
- Where
- South Korea
- Volunteers
- 4,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypertension, Congestive Heart Failure
To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure
To compare and evaluate the efficacy and safety of Candemore tab. versus Atacand tab. on blood pressure in patients with hypertension diagnosed congestive heart failure
- Trial name
- CANTABILE (NCT01682564)
- Testing
- Candemore tablet, Atacand tablet
- Where
- 14 sites in South Korea
- Volunteers
- 169 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Effectiveness of a Valsartan Based vs an Amlodipine Based Treatment Strategy in naïve Patients With Stage 1 or Stage 2 Hypertension or in Patients Uncontrolled on Current Monotherapy
Essential hypertension is a widespread disease which affects one out of every three adults in the industrialized world. It contributes to cardiovascular disease development, a major and well established risk factor.
- Trial name
- NCT00351130
- Testing
- valsartan, amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 79 people
- Sponsor
- Novartis
Resistant Hypertension
A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.
The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.
- Trial name
- NCT00272961
- Testing
- TBC3711
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Hypertension
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
This is a study for people diagnosed with hypertension to compare 3 doses (75 mg, 150 mg, and 300 mg) of an experimental product, aliskiren in comparison to a placebo. Each patient is in the study for 8 weeks
- Trial name
- NCT00260923
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 641 people
- Sponsor
- Novartis
High Blood Pressure (Hypertension).
Factorial Study of Metoprolol Succinate TOPROL-XL (324A)
The purpose of this research study is to determine if treatment with the combination of metoprolol succinate and hydrochlorothiazide is more effective at lowering blood pressure than treatment with either of the two drugs alone.
- Trial name
- NCT00642096
- Testing
- Metoprolol Succinate, Hydrochlorothiazide
- Volunteers
- 1,900 people
- Sponsor
- AstraZeneca